• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology
    Get the next $TGAN alert in real time by email

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23%

    - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter

    - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value

    - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024").

    Primit Parikh, Transphorm's CEO and Co-Founder, commented, "In Q2 Fiscal 2024 we saw strong sequential and year-over-year product sales growth accompanied by improved gross margin that nearly doubled year-over-year. We were pleased with the continued growth of our pipeline and our design wins, highlighted by record growth in high-power design wins. We anticipate continued strong growth in product revenue in our third fiscal quarter as we realize the benefits of converting our burgeoning design-ins into revenue generating contracts."

    Dr. Parikh continued, "Importantly, we engaged BofA Securities to advance our previously announced strategic review process, and we are continuing this process as we seek to enhance stockholder value, pursuing multiple options that include the potential merger or sale of the company."

    Key Business Highlights

    • Reported total revenue of $5.0 million for Q2 Fiscal 2024, an increase of 36.5% over the same quarter last year and a decrease of 15% from the prior quarter.
    • Product revenue was $3.55 million in the quarter, exceeding the Company's expectations, with an increase of 12% from the same quarter last year and 18% over the prior quarter. Government revenue was $1.46 million in the quarter versus $2.9 million in the prior quarter.
    • Gross margin in the quarter was 23.4%, exceeding the Company's expectations, with an increase of 11.5% year-over-year, while down from 35.5% in the prior quarter due to lower mix of government contract revenue.
    • Continued to grow its 5-year pipeline opportunity—now at over $475 million, of which about 70% is in high power, and also up 5% from the Company's previous update in August 2023. With traction in design-ins and opportunities entering or nearing production, the Company expects a continuation of its sequential product revenue growth in the third quarter of fiscal 2024.
    • Became the first and only GaN company to surpass 200 billion field operation hours for GaN products, including both low power and high power.
    • Announced the publication of the Company's white paper, The Fundamental Advantages of D-Mode GaN in Cascode Configuration. The paper lays out how Transphorm's normally-off D-Mode platform design harnesses GaN's natural benefits, whereas E-Mode designs must make certain performance compromises.
    • The Company's GaN became the first to demonstrate a short circuit robustness milestone key to motor drive and automotive EV inverter applications.
    • Closed common stock only $7.94 million Rights Offering at $3.30 per share.

    High Power Segment Update – Continued Leadership of Transphorm in GaN

    • Increased total design-ins for higher power (300 watt – 7.5 kilowatt) to over 100 (with over 35 in production), an increase of more than 30% from the Company's previous update in August 2023, with an estimated 75% plus conversion rate in the markets from design-in to in production.
    • Breakthrough production win with solar inverter player - Announced Transphorm's GaN platform powers the world's first integrated photovoltaic (PV) systems from DAH Solar Co., Ltd. (Anhui Daheng New Energy Technology Co., LTD.), enabling it to produce smaller, lighter, and more reliable solar panel systems that also offer higher overall power generation with lower energy consumption.
    • Introduced three SuperGaN® FETs in surface mount devices (SMD) TOLL packages supporting higher power applications operating within an average range of 1 to 3 kilowatts typically found in high performance segments such as computing (AI, server, telecom, data center), energy and industrial (PV inverters, servo motors), and other broad industrial markets.
    • Expanded the Company's package option portfolio launching the SuperGaN® TOLT FET with an on-resistance of 72 milliohms, the industry's first top-side cooled surface mount GaN device in the JEDEC-standard (MO-332) TOLT package.
    • Another first for Transphorm GaN is the initial sampling of the TO-247-4 lead package (drop in with Si and SiC solutions), with recent internal tests demonstrating 25% lower losses versus similar SiC -MOSFET offerings from a global top-3 supplier, thereby increasing the socket penetration opportunities with new and existing solutions.
    • Transphorm is actively engaged with multiple global customer partners for high power GaN in these new surface mount packages, a global leader in the microinverter space, lead customers in server and storage power, an innovative manufacturer for off-grid power solutions and a leader in satellite communications.
    • Released 300W and 600W Electric 2 and 3-wheeler charger power supply designs and successfully designed into 2 of the top 5 India OEMs in 2-wheeler battery chargers.

    Low Power Segment Update – Transphorm Enables Superior Performance

    • Increased total design-ins for power adapters and fast chargers (< 300 watt) to over 115 (with over 30 in production), an increase in ongoing design-ins of 15% from the Company's previous update in August 2023.
    • Expanded the Company's System-In-Package (SiP) strategy to over five IC partners, to enable faster growth in this segment.
    • Continued to expand sockets at two of the top three world-wide laptop OEMs in multiple power levels – both at 65W and higher range from 100W to 360W.

    Cameron McAulay, Transphorm's CFO, said, "We significantly outperformed our gross margin expectations this quarter at 23%, and we continue to progress toward our long-term model of gross margins in excess of 40%. Additionally, we meaningfully reduced cash burn from $6.8 million for the first quarter of fiscal 2024 to $5.1 million for Q2 Fiscal 2024, and we continue to have zero debt on our balance sheet, which puts us in a strong position to secure additional non-dilutive funding."

    Q2 Fiscal 2024 Financial Results

    Revenue increased $1.3 million, or 36.5%, to $5.0 million for Q2 Fiscal 2024 from $3.7 million for the same period in 2022 ("Q2 Fiscal 2023"). Product Revenue increased by $0.5 million, or 18% from Q1 Fiscal 2024 and increased by $0.4 million, or 12%, from Q2 Fiscal 2023. Government contract revenue was up $1.0 million year-over-year and down $1.4 million from the prior quarter.

    Operating expenses were $7.7 million in Q2 Fiscal 2024, compared to $8.9 million in the previous quarter and $5.9 million in Q2 Fiscal 2023. Q2 Fiscal 2024 operating expenses consisted of R&D expenses of $3.0 million and SG&A expenses of $4.7 million. Operating expenses on a non-GAAP basis were $6.4 million in Q2 Fiscal 2024, a decrease compared to the previous quarter and up from $5.2 million in Q2 Fiscal 2023.

    Net loss for Q2 Fiscal 2024 was ($7.1) million, or ($0.12) per share, compared to net loss of ($7.4) million, or ($0.22) per share, in the prior quarter, and net loss of ($6.0) million, or ($0.10) per share, in Q2 Fiscal 2023. On a non-GAAP basis, adjusted EBITDA for Q2 Fiscal 2024 was ($5.0) million, or ($0.08) per share, compared to non-GAAP adjusted EBITDA of ($4.5) million, or ($0.08) per share, in the prior quarter, and non-GAAP adjusted EBITDA of ($4.6) million, or ($0.08) per share, in Q2 Fiscal 2023.

    Cash, cash equivalents and restricted cash as of September 30, 2023, were $6.2 million.

    Conference Call and Webcast Information

    Event:

     

    Transphorm Fiscal 2024 Second Quarter Financial Results

    Date:

     

    Thursday, November 9, 2023

    Time:

     

    5:00 p.m. Eastern Standard Time

    Webcast:

     

    https://edge.media-server.com/mmc/p/fwqsmkh3/

    Conference Call:

     

    https://register.vevent.com/register/BI343d7375eaee4e4eabbebab82cec1757

    A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company's website.

    About Transphorm

    Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry's leading JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company's vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm's innovations move power electronics beyond the limitations of silicon to achieve over 99% efficiency, 50% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm GaN.

    Non-GAAP Financial Measures

    This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

    Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm's ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm's results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income and expenses.

    A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company's strategic review process; the Company's 5-year pipeline and anticipated future growth; the Company's expectation that sequential product revenue growth will continue in the third quarter of fiscal 2024; the Company's expectations for future products, design-ins and market acceptance; and the information set forth in the quotes by the Company's management set forth herein. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: prevailing market conditions; that the Company's current forecasted cash runway, without any additional financing, may not last as long as anticipated; that the Company's anticipated strategic review may not result in any transaction (or that the terms of such transaction may not be favorable or acceptable to the Company or its stockholders); risks related to the Company's operations, such as additional financing requirements, access to capital and market acceptance of its current and future products; competition; the Company's ability to protect its intellectual property rights; and other risks set forth in the Company's filings with the Securities and Exchange Commission, including under the caption "Risk Factors" and elsewhere therein. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Transphorm, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands)

    (Unaudited)

     

     

    September 30, 2023

     

    March 31, 2023

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    6,152

     

     

    $

    15,527

     

    Restricted cash

     

    —

     

     

     

    500

     

    Accounts receivable

     

    4,571

     

     

     

    4,396

     

    Inventory

     

    9,776

     

     

     

    8,406

     

    Prepaid expenses and other current assets

     

    1,426

     

     

     

    1,859

     

    Total current assets

     

    21,925

     

     

     

    30,688

     

    Property and equipment, net

     

    7,857

     

     

     

    7,890

     

    Operating lease right-of-use assets

     

    2,719

     

     

     

    3,033

     

    Goodwill

     

    963

     

     

     

    1,079

     

    Intangible assets, net

     

    173

     

     

     

    321

     

    Investment in joint venture

     

    —

     

     

     

    715

     

    Other assets

     

    652

     

     

     

    726

     

    Total assets

     

    34,289

     

     

    $

    44,452

     

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable and accrued expenses

     

    6,198

     

     

    $

    7,895

     

    Accrued interest

     

    —

     

     

     

    180

     

    Unfunded commitment in joint venture

     

    59

     

     

     

    —

     

    Accrued payroll and benefits

     

    1,557

     

     

     

    1,458

     

    Operating lease liabilities

     

    525

     

     

     

    404

     

    Revolving credit facility

     

    —

     

     

     

    12,000

     

    Total current liabilities

     

    8,339

     

     

     

    21,937

     

    Operating lease liabilities, net of current portion

     

    2,259

     

     

     

    2,670

     

    Other liabilities

     

    —

     

     

     

    230

     

    Total liabilities

     

    10,598

     

     

     

    24,837

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    6

     

     

     

    6

     

    Additional paid-in capital

     

    255,249

     

     

     

    230,272

     

    Accumulated deficit

     

    (229,424

    )

     

     

    (209,236

    )

    Accumulated other comprehensive loss

     

    (2,140

    )

     

     

    (1,427

    )

    Total Stockholders' equity

     

    23,691

     

     

     

    19,615

     

    Total liabilities and stockholders' equity

     

    34,289

     

     

    $

    44,452

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Operations (unaudited)

    (in thousands except share and per share data)

     

     

    Three Months Ended

     

    Six Months Ended

     

    September 30,

    2023

     

    June 30,

    2023

     

    September 30,

    2022

     

    September 30,

    2023

     

    September 30,

    2022

    Revenue, net

    $

    5,010

     

     

    $

    5,883

     

     

    $

    3,670

     

     

    $

    10,893

     

     

    $

    8,826

     

    Cost of goods sold

     

    3,836

     

     

     

    3,795

     

     

     

    3,232

     

     

     

    7,631

     

     

     

    7,282

     

    Gross profit

     

    1,174

     

     

     

    2,088

     

     

     

    438

     

     

     

    3,262

     

     

     

    1,544

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

    Research and development

     

    3,022

     

     

     

    2,869

     

     

     

    1,830

     

     

     

    5,891

     

     

     

    3,570

     

    Sales and marketing

     

    1,708

     

     

     

    1,482

     

     

     

    1,066

     

     

     

    3,190

     

     

     

    2,149

     

    General and administrative

     

    2,942

     

     

     

    4,516

     

     

     

    3,044

     

     

     

    7,458

     

     

     

    6,361

     

    Total operating expenses

     

    7,672

     

     

     

    8,867

     

     

     

    5,940

     

     

     

    16,539

     

     

     

    12,080

     

    Loss from operations

     

    (6,498

    )

     

     

    (6,779

    )

     

     

    (5,502

    )

     

     

    (13,277

    )

     

     

    (10,536

    )

    Interest expense

     

    —

     

     

     

    8

     

     

     

    184

     

     

     

    8

     

     

     

    366

     

    Loss in joint venture

     

    721

     

     

     

    860

     

     

     

    684

     

     

     

    1,581

     

     

     

    1,266

     

    Other income, net

     

    (90

    )

     

     

    (200

    )

     

     

    (375

    )

     

     

    (290

    )

     

     

    (820

    )

    Loss before tax expense

     

    (7,129

    )

     

     

    (7,447

    )

     

     

    (5,995

    )

     

     

    (14,576

    )

     

     

    (11,348

    )

    Tax expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Net loss

    $

    (7,129

    )

     

    $

    (7,447

    )

     

    $

    (5,995

    )

     

    $

    (14,576

    )

     

    $

    (11,348

    )

     

     

     

     

     

     

     

     

     

     

    Deemed dividend related to warrant modification and issuance of Inducement Warrants

     

    —

     

     

     

    5,612

     

     

     

    —

     

     

     

    5,612

     

     

     

    —

     

    Net loss attributable to common shareholders

    $

    (7,129

    )

     

    $

    (13,059

    )

     

    $

    (5,995

    )

     

    $

    (20,188

    )

     

    $

    (11,348

    )

     

     

     

     

     

     

     

     

     

     

    Net loss per share - basic and diluted

    $

    (0.12

    )

     

    $

    (0.22

    )

     

    $

    (0.10

    )

     

    $

    (0.33

    )

     

    $

    (0.20

    )

    Weighted average common shares outstanding - basic and diluted

     

    61,138,691

     

     

     

    59,264,378

     

     

     

    56,619,662

     

     

     

    61,071,729

     

     

     

    55,518,297

     

    Transphorm, Inc.

    Reconciliation of GAAP and Non-GAAP Financial Information (unaudited)

    (in thousands except per share data)

     

     

    Three Months Ended

     

    Six Months Ended

     

    September 30,

    2023

     

    June 30,

    2023

     

    September 30,

    2022

     

    September 30,

    2023

     

    September 30,

    2022

    GAAP net loss

    $

    (7,129

    )

     

    $

    (7,447

    )

     

    $

    (5,995

    )

     

    $

    (14,576

    )

     

    $

    (11,348

    )

    Adjustments:

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    914

     

     

     

    2,003

     

     

     

    636

     

     

     

    2,916

     

     

     

    1,219

     

    Depreciation

     

    269

     

     

     

    196

     

     

     

    165

     

     

     

    465

     

     

     

    317

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

     

     

    148

     

     

     

    148

     

    Provision for doubtful accounts

     

    263

     

     

     

    —

     

     

     

    —

     

     

     

    263

     

     

     

    —

     

    Total other expense, net

     

    631

     

     

     

    668

     

     

     

    493

     

     

     

    1,299

     

     

     

    812

     

    Total adjustments to GAAP net loss

     

    2,151

     

     

     

    2,941

     

     

     

    1,368

     

     

     

    5,091

     

     

     

    2,496

     

    Non-GAAP adjusted EBITDA

    $

    (4,978

    )

     

    $

    (4,506

    )

     

    $

    (4,627

    )

     

    $

    (9,485

    )

     

    $

    (8,852

    )

    GAAP net loss per share - basic and diluted

    $

    (0.12

    )

     

    $

    (0.22

    )

     

    $

    (0.10

    )

     

    $

    (0.33

    )

     

    $

    (0.20

    )

    Adjustment

     

    0.04

     

     

     

    0.14

     

     

     

    0.02

     

     

     

    0.17

     

     

     

    0.04

     

    Non-GAAP adjusted EBITDA per share - basic and diluted

    $

    (0.08

    )

     

    $

    (0.08

    )

     

    $

    (0.08

    )

     

    $

    (0.16

    )

     

    $

    (0.16

    )

    Weighted average common shares outstanding - basic and diluted

     

    61,138,691

     

     

     

    59,264,378

     

     

     

    56,619,662

     

     

     

    61,071,729

     

     

     

    55,518,297

     

     

    Three Months Ended

     

    Six Months Ended

     

    September 30,

    2023

     

    June 30,

    2023

     

    September 30,

    2022

     

    September 30,

    2023

     

    September 30,

    2022

    GAAP operating expenses

    $

    7,672

     

    $

    8,867

     

    $

    5,940

     

    $

    16,539

     

    $

    12,080

    Adjustments:

     

     

     

     

     

     

     

     

     

    Stock-based compensation

     

    819

     

     

     

    1,865

     

     

     

    583

     

     

     

    2,685

     

     

     

    1,126

     

    Depreciation

     

    98

     

     

     

    99

     

     

     

    96

     

     

     

    197

     

     

     

    191

     

    Amortization

     

    74

     

     

     

    74

     

     

     

    74

     

     

     

    148

     

     

     

    148

     

    Provision for doubtful accounts

     

    263

     

     

     

    —

     

     

     

    —

     

     

     

    263

     

     

     

    —

     

    Total adjustments to GAAP operating expenses

     

    1,254

     

     

     

    2,038

     

     

     

    753

     

     

     

    3,293

     

     

     

    1,465

     

    Non-GAAP operating expenses

    $

    6,418

     

     

    $

    6,829

     

     

    $

    5,187

     

     

    $

    13,246

     

     

    $

    10,615

     

    Transphorm, Inc.

    Condensed Consolidated Statements of Cash Flows (unaudited), (in thousands)

     

     

    Six Months Ended September 30,

     

    2023

     

    2022

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (14,576

    )

     

    $

    (11,348

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

    Provision for inventory

     

    139

     

     

     

    56

     

    Depreciation and amortization

     

    613

     

     

     

    465

     

    Amortization of right-of-use assets

     

    268

     

     

     

    286

     

    Provision for doubtful accounts

     

    263

     

     

     

    —

     

    Stock-based compensation

     

    2,916

     

     

     

    1,219

     

    Interest cost

     

    —

     

     

     

    4

     

    Gain on sale of equipment

     

    (48

    )

     

     

    (110

    )

    Loss in joint venture

     

    1,581

     

     

     

    1,266

     

    Changes in fair value of derivative instruments

     

    171

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (437

    )

     

     

    941

     

    Inventory

     

    (1,509

    )

     

     

    (2,692

    )

    Prepaid expenses and other current assets

     

    426

     

     

     

    (97

    )

    Other assets

     

    74

     

     

     

    (521

    )

    Accounts payable, accrued expenses, and other liabilities

     

    (2,615

    )

     

     

    904

     

    Deferred revenue

     

    —

     

     

     

    (83

    )

    Accrued payroll and benefits

     

    99

     

     

     

    160

     

    Operating lease liabilities

     

    (245

    )

     

     

    (263

    )

    Net cash used in operating activities

     

    (12,880

    )

     

     

    (9,813

    )

    Cash flows from investing activities:

     

     

     

    Purchases of property and equipment

     

    (590

    )

     

     

    (4,026

    )

    Proceeds from sale of equipment

     

    48

     

     

     

    110

     

    Investment in joint venture

     

    (807

    )

     

     

    (1,537

    )

    Net cash used in investing activities

     

    (1,349

    )

     

     

    (5,453

    )

    Cash flows from financing activities:

     

     

     

    Proceeds from stock option exercise

     

    —

     

     

     

    56

     

    Proceeds from issuance of common stock

     

    9,936

     

     

     

    16,000

     

    Cost associated with issuance of common stock

     

    (117

    )

     

     

    (280

    )

    Payment for taxes related to net share settlement of restricted stock units

     

    (288

    )

     

     

    (6

    )

    Proceeds from exercise of stock warrants

     

    7,263

     

     

     

    —

     

    Loan repayment

     

    (12,000

    )

     

     

    —

     

    Net cash provided by financing activities

     

    4,794

     

     

     

    15,770

     

    Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     

    (440

    )

     

     

    (443

    )

    Net (decrease) increase in cash, cash equivalents and restricted cash

     

    (9,875

    )

     

     

    61

     

    Cash, cash equivalents and restricted cash at beginning of period

     

    16,027

     

     

     

    33,935

     

    Cash, cash equivalents and restricted cash at end of period

    $

    6,152

     

     

    $

    33,996

     

    Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets

     

     

     

    Cash and cash equivalents

    $

    6,152

     

     

    $

    33,496

     

    Restricted cash

     

    —

     

     

     

    500

     

    Cash, cash equivalents and restricted cash at end of period

    $

    6,152

     

     

    $

    33,996

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231109916829/en/

    Get the next $TGAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TGAN

    DatePrice TargetRatingAnalyst
    6/15/2022$9.00 → $6.50Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $TGAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Transphorm downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Transphorm from Buy to Neutral and set a new price target of $6.50 from $9.00 previously

    6/15/22 7:40:43 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Demonstrates a Bidirectional SuperGaN Power Supply with New Reference Design for E-Mobility and Energy/Industrial Markets

    300 W DC-to-DC Battery Charger Board Showcases Key Capability of GaN Technology Necessary to Advance E-Mobility Applications Transphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced the release of a new 300 W DC-to-DC GaN reference design for 2- and 3-wheeled electric vehicle battery chargers. The TDDCDC-TPH-IN-BI-LLC-300W-RD design uses TP65H150G4PS 150 mOhm SuperGaN® FETs in a robust TO-220 package to power a high performing, high efficiency energy harvesting and distribution battery charging system. The new board notably demonstrates one of the most anticipated value propositions of a GaN power supply: bidirectionality. This capability indic

    6/11/24 3:00:00 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    SEC Filings

    View All

    SEC Form 15-12G filed by Transphorm Inc.

    15-12G - Transphorm, Inc. (0001715768) (Filer)

    7/1/24 9:01:49 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:13 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form EFFECT filed by Transphorm Inc.

    EFFECT - Transphorm, Inc. (0001715768) (Filer)

    6/21/24 12:15:04 AM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kkr Phorm Investors L.P. sold $124,501,037 worth of shares (24,411,968 units at $5.10) (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:30:24 PM ET
    $TGAN
    Semiconductors
    Technology

    PRESIDENT AND CEO Parikh Primit returned 489,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:22 PM ET
    $TGAN
    Semiconductors
    Technology

    Chief Financial Officer Mcaulay Cameron returned 182,048 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Transphorm, Inc. (0001715768) (Issuer)

    6/20/24 4:05:17 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Transphorm Inc.

    SC 13D/A - Transphorm, Inc. (0001715768) (Subject)

    6/20/24 4:30:51 PM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/14/24 10:15:50 AM ET
    $TGAN
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Transphorm Inc. (Amendment)

    SC 13G/A - Transphorm, Inc. (0001715768) (Subject)

    2/13/24 1:41:50 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Financials

    Live finance-specific insights

    View All

    Renesas Completes Acquisition of Transphorm

    Accelerates Wide Bandgap Product Offering and Introduces 15 New GaN-Based Winning Combination Reference Designs Renesas Electronics Corporation ("Renesas" TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that it has completed the acquisition of Transphorm, Inc. (NASDAQ:TGAN), a global leader in gallium nitride (GaN) power semiconductors, as of June 20, 2024. With the closing of the acquisition now completed, Renesas will immediately start offering GaN-based power products and related reference designs to meet the rising demand for wide bandgap (WBG) semiconductor products. This press release features multimedia. View the full release here: https://www.bu

    6/20/24 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Third Quarter Results and Provides Business Update

    Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the third quarter of its fiscal year ending March 31, 2024 ("Q3 Fiscal 2024"). On January 10, 2024, Transphorm announced that it entered into a definitive agreement to be acquired by a subsidiary of Renesas Electronics Corporation. The transaction values Transphorm at approximately $339 million. Key Business Highlights Reported total revenue of $4.7 million for Q3 Fiscal 2024, an increase of 4.0% over the same quarter last year and a decrease of 6.8% from the prior quarter. Product revenue was $3.2 million in the quarter, a decrease of 20%

    2/20/24 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Announces Fiscal 2024 Second Quarter Results and Provides Business Update

    - Reports Second Quarter Year-Over-Year Revenue Grew 37% to $5.0 Million as Gross Margin Increased by 11.5% to 23% - Product Revenue Increased to $3.55 Million, Up 18% Over the Prior Quarter - Recently Engaged BofA Securities, Inc. to Act as Financial Advisor in Company's Strategic Review to Enhance Stockholder Value - Company to Host Webcast Today at 5:00 p.m. EST to Review Quarterly Results and Provide a Business Update Transphorm, Inc. (NASDAQ:TGAN)—a global leader in GaN, the future of next generation power systems, announced today its financial results for the second quarter of its fiscal year ending March 31, 2024 ("Q2 Fiscal 2024"). Primit Parikh, Transphorm's CEO and Co-Fo

    11/9/23 4:05:00 PM ET
    $TGAN
    Semiconductors
    Technology

    $TGAN
    Leadership Updates

    Live Leadership Updates

    View All

    Efinix Appoints Cameron McAulay as Chief Financial Officer

    McAulay Brings a Decade of Public-Company Semiconductor CFO Experience to Support Efinix's Global Expansion Efinix, Inc., the FPGA pioneer accelerating edge AI innovation, today announced the appointment of Cameron McAulay as Chief Financial Officer and Senior Vice President Finance. McAulay brings more than 20 years of financial leadership experience in the semiconductor and technology industries, including over a decade of service as CFO at publicly traded companies, making him uniquely qualified to help guide Efinix through its next stage of growth and value creation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303081

    3/3/26 11:00:00 AM ET
    $IVAC
    $TGAN
    Industrial Machinery/Components
    Technology
    Semiconductors

    Transphorm Announces Appointment of Company Co-founders as Chief Executive Officer and Board Chair

    Follows Retirement of CEO and as part of the Company's Planned Succession Strategy Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and global supplier of high-reliability, high-performance gallium nitride (GaN) power conversion products, announced that its Board of Directors has appointed Dr. Primit Parikh as President and Chief Executive Officer of the Company and as a member of the Board. The Board also appointed Dr. Umesh Mishra to serve as Chair of the Board. Both of these appointments are effective May 15, 2023. Dr. Parikh and Dr. Mishra, who co-founded the Company's main operating subsidiary Transphorm Technology Inc., succeed Mario Rivas, who has served as the Company's Chief Executi

    5/15/23 8:30:00 AM ET
    $TGAN
    Semiconductors
    Technology

    Transphorm Appoints Six Company Leaders

    Company Veterans and Industry Leaders to Drive Next Phase of Growth Transphorm, Inc. (NASDAQ:TGAN)—a pioneer in and a global supplier of high reliability, high performance gallium nitride (GaN) power conversion products—announced today the appointment of six company leaders. The roles are being filled by company veterans as well as newly hired experts, strategically building out Transphorm's executive bench. The collective sales, operations, engineering, and product marketing skillsets brought by these individuals will contribute to Transphorm's business growth and customer support strategies as the company responds to a rapidly rising demand for high voltage GaN power semiconductors acros

    10/27/22 9:00:00 AM ET
    $TGAN
    Semiconductors
    Technology